



HHS PUBLIC ACCESS

Author manuscript

J Nat Prod. Author manuscript; available in PMC 2017 November 23.

Published in final edited form as:

J Nat Prod. 2016 November 23; 79(11): 2890–2897. doi:10.1021/acs.jnatprod.6b00646.

Total Synthesis and in Vitro Anti-Tumor-Promoting Activities of Racemic Acetophenone Monomers from *Acronychia trifoliolata*

Chihiro Morita[†], Yukiko Kobayashi[†], Yohei Saito[†], Katsunori Miyake[†], Harukuni Tokuda[‡], Nobutaka Suzuki[§], Eiichiro Ichiishi[⊥], Kuo-Hsiung Lee^{||, #}, and Kyoko Nakagawa-Goto^{*, †, ||}

[†]School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan

[§]Department of Complementary and Alternative Medicine, Clinical R&D, Graduate School of Medical Science, Kanazawa University, Kanazawa, 920-1192, Japan

[‡]Organic Chemistry in Life Science, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan

[⊥]International Health & Welfare University Hospital, Nasushiobara, Tochigi 329-2763, Japan

^{||}Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7568, United States

[#]Chinese Medicine Research and Development Center, China Medical University and Hospital, 2 Yuh-Der Road, Taichung, 40447, Taiwan

Abstract

Six acetophenone derivatives, acronyculatins I (**1**), J (**2**), K (**3**), L (**4**), N (**5**), and O (**6**), were recently isolated from *Acronychia trifoliolata*, and the structure of the known acronyculatin B (**7**) was revised. Because of the limited quantities of isolated products as well as their structure similarity, racemic acronyculatins I–L, N, O, and B (**1–7**) were synthesized to confirm their structures and to obtain sufficient material for biological evaluation. Trihydroxyacetophenone was converted to the target compounds by various sequences of hydroxy group protection, allylation or prenylation, and epoxidation followed by cyclization. *C*-Prenylations were carried out by direct addition of a prenyl group or through 1,3- or 3,3-sigmatropic rearrangement. The synthesized racemic compounds were evaluated in an anti-tumor-promoting assay using the Epstein–Barr virus early antigen (EBV-EA) activation induced by 12-*O*-tetradecanoylphorbol-13-acetate in Raji cells. All tested compounds significantly inhibited EBV-EA activation. Especially, racemic acronyculatin I (**1**) displayed the most potent inhibitory effects, with an IC₅₀ value of 7.3 μ M.

Graphical abstract

*Corresponding Author: Tel (K. Nakagawa-Goto): +81-76-264-6305. kngoto@p.kanazawa-u.ac.jp.


Notes

The authors declare no competing financial interest.

Supporting Information


The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnat-prod.6b00646.

¹H NMR/¹³C NMR for **1–7**, **14–18**, **20–23**, and **25–30**, the experimental procedures for known compounds **9–13**, **19**, and **24** (PDF)



Prenylated acetophenones are mainly distributed in specific genera of the Rutaceae, such as *Acradenia*, *Bosistoa*, *Melicope*, *Medicosma*, and *Acronychia*.¹ In rare cases, they are found in the root bark of *Derris indica*² and Brazilian propolis.³ More than 50 prenylated acetophenones have been isolated from the above species.¹ The prenyl group(s) is sometimes cyclized with a neighboring phenolic oxygen to form a pyran or furan ring. Interesting dimeric acetophenones, such as acrove-stone, acropyrone, and acropyraonols, are found only in *Acronychia*.⁴⁻⁸

Acronychia trifoliolata Zoll. & Moritzi is distributed from Java and Christmas Island to the Solomon Islands, and only one phytochemical study has been reported on this species.⁷ In the course of the discovery of unknown bioactive natural products from rainforest plants, six new acetophenone monomers, named acronyculatins I (1), J (2), K (3), L (4), M, N (5), and O (6), were isolated from a 1:1 CH₃OH/CH₂Cl₂ extract of this plant.⁹ In addition, the structure of acronyculatin B (7), originally identified by Su et al.,¹⁰ was revised to be 1-[6-hydroxy-2-(2-hydroxypropan-2-yl)-4-methoxy-7-(3-methylbut-2-en-1-yl)-2,3-dihydrobenzofuran-5-yl]ethan-1-one based on extensive NMR studies. Because the isolation was performed on a limited amount (4.9 g) of extract provided by the U.S. National Cancer Institute (NCI), and no more material was available, small quantities of each compound were obtained. However, all isolated compounds were successfully identified using various NMR, HRMS, and IR techniques. Compounds 1-7 showed weak or no antiproliferative activity.⁹ However, prior studies have indicated that acetophenone derivatives display potent inhibition of tumor-promoting activities.^{11,12} In addition, the importance of a prenyl-like functional group was discussed in our previous reports.¹³⁻¹⁶ Thus, prenylated acetophenones, such as the acronyculatins, could significantly inhibit the tumor-promoting activities. To confirm the structure elucidation as well as provide sufficient quantities of materials for further bioassays, the total syntheses of racemic acronyculatins 1-7 were performed. Herein, the synthesis details and evaluation of the anti-tumor-promoting activities are described.



RESULTS AND DISCUSSION

Since acetophloroglucinol is the core skeleton for all target compounds, 2,4,6-trihydroxyacetophenone (**8**) was selected as the starting material. Scheme 1 illustrates the synthesis of acetophenone monomers **1–5**. Two hydroxy groups of trihydroxyacetophenone (**8**) were first protected as methoxymethyl (MOM) ethers to provide **9**. Prenylation of the hydrogen-bonded phenolic group, followed by microwave-assisted *para*-Claisen rearrangement, produced **10**,¹⁷ which was methylated with MeI to generate **11**. The selective removal of only one MOM protecting group was achieved successfully by controlled reaction conditions in 3 N HCl/MeOH (1:10 v/v) solution. Treatment of **12**¹⁸ with *m*-chloroperoxybenzoic acid (*m*-CPBA) afforded an epoxide, and subsequent cyclization to the chromane **14** was catalyzed by montmorillonite K10 clay.¹⁹ The removal of the remaining MOM group, prenylation of the phenolic group, and 1,3-rearrangement of the prenyl group using montmorillonite K10²⁰ gave racemic acronyculatin L (**4**). Racemic acronyculatin K (**3**) was synthesized similarly from **11**. Both MOM groups were removed by using more concentrated acidic conditions [3 N HCl/MeOH (1:5 v/v)] than those mentioned above for the selective removal of one MOM group. Two subsequent reactions (*m*-CPBA, montmorillonite K10 clay) on the resulting **13**^{18,21} produced only **16**, in which cyclization had occurred via the non-hydrogen-bonded hydroxy group. The *O*-prenylation and microwave-assisted *para*-Claisen rearrangement of **16** gave racemic acronyculatin K (**3**). Catalytic reduction of **3** produced unnatural compound **18**, a regioisomer of **2**.

Compound **8** was treated with prenyl bromide in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)²² to generate monoprenylated acetophenone **19**, which was converted to **20** by MOM protection, methylation, and deprotection of MOM groups. Dihydroxyacetophenone **20** was treated with *m*-CPBA and montmorillonite K10 clay to afford **21**. Prenylation of the phenolic group and subsequent 1,3-rearrangement gave racemic acronyculatin I (**1**), which was converted to racemic acronyculatin J (**2**) by catalytic reduction. Racemic acronyculatin M (**5**) was prepared from di-MOM ether **9**. *O*-Allylation of the phenolic group and subsequent microwave-assisted 3,3-sigmatropic rearrangement of the allyl ether produced **22**. Deprotection of both MOM groups gave **23**. Oxidative cleavage of the terminal olefinic bond was followed by spontaneous hemiacetalization to provide **5**.

As shown in Scheme 2, the prenylation of trihydroxyacetophenone **8** in the presence of 10% KOH produced diprenylated acetophenone **24**, which was converted to **25** through a three-step sequence, i.e., disilylation using *tert*-butyldimethylsilyl chloride (TBSCl), methylation, and selective deprotection²³ of the TBS ether. Treatment of **25** with 1 molar equiv of *m*-CPBA at low temperature resulted in nonselective monoepoxidation of the olefinic functional groups. The resulting two products were probably the dihydrobenzofuran **31**, which was spontaneously cyclized through **27a**, and epoxide **27b**. To avoid the unfavorable cyclization, the phenolic moiety on **25** was protected as the acetate to give **26**. The monoepoxidation of **26** under the above conditions afforded **28a** and **28b** as an inseparable ca. 1:3 mixture by ¹H NMR analysis. The removal of the TBS group with tetra-*n*-butylammonium fluoride (TBAF)/HOAc prompted cyclization to the separable dihydrobenzofurans **29** and **30** in 27% and 64% yield, respectively. Under the same

conditions, no chromane type of product was obtained, while the use of KF/18-crown-6/TFA at -10°C generated **32** as a minor product and dihydrobenzofurans **29** and **30**. Hydrolysis of the acetoxy group of **29** and **30** by using $\text{Ba}(\text{OH})_2$ generated racemic acronyculatins O (**6**) and B (**7**) in 56% and 53% yield, respectively.

The structures of the compounds were defined via HRMS and NMR data and were consistent with the assigned structures of the compounds⁹ isolated from *A. trifoliolata* Zoll. & Moritzi.

As mentioned above, previous studies have indicated that prenyl-like structures and acetophenone derivatives tend to show potent effects on inhibition of 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-mediated tumor-promoting activity.^{11–16} Thus, compounds **1–7**, **18**, **29**, and **30** were evaluated for cancer chemopreventive activity by means of the Epstein–Barr virus early antigen (EBV-EA) activation stimulated by TPA in Raji cells. It has been proven that inhibitory effects on EBV-EA activation correlate well with anti-tumor-promoting activity in vivo, as was previously reported for several natural product derivatives, such as the analogues of dimethyl biphenyldicarboxylate,¹³ betulinic acid,^{15,24} and coumarins.^{16,25}

As shown in Table 3, the tested compounds displayed low to moderate cytotoxicity, as shown by high viability (60%) of Raji cells, implying less than 40% growth inhibition, even at a high concentration of TPA (32 nmol, a compound/TPA molar ratio of 1000:1). Furthermore, all compounds significantly inhibited TPA-mediated EBV-EA activation. Racemic acronyculatin I (**1**) showed the most potent inhibitory activity, with 100% inhibition of EBV-EA activation at the highest concentration (1000 mol ratio/TPA) and 7.6% inhibition at the lowest tested concentration (10 mol ratio/TPA). The IC_{50} value was $7.3\ \mu\text{M}$. Among the phenolic compounds **1–7** and **18**, compound **5**, devoid of a prenyl group, clearly exhibited reduced activity. These data supported the previous observations that a prenyl or prenyl-like group plays an important role in anti-tumor-promoting effects. Interestingly, the position of functional groups slightly affected the activity in the case of compounds with a chromane skeleton (**1** vs **3** and **2** vs **18**), while no difference was observed between the two compounds with a dihydrobenzofuran skeleton (**6** vs **7**). In addition, with the latter two compounds, the absence of a phenolic group led to decreased activity (**6** vs **29** and **7** vs **30**).

In summary, seven racemic acronyculatins isolated from *A. trifoliolata* Zoll. & Moritzi. and the acetophenone monomer **18** were synthesized. The NMR spectra of the synthetic racemic acronyculatins B and I–O were identical to those of the natural products. Evaluation of anti-tumor-promoting activity revealed that all tested acetophenones significantly inhibited EBV-EA activation induced by TPA in Raji cells. Especially, racemic acronyculatin I (**1**) displayed the most potent activity.

EXPERIMENTAL SECTION

General Experimental Procedures

Optical rotations were recorded on a JASCO P-2200 digital polarimeter. Infrared spectra (IR) were measured with a Shimadzu FTIR-8700 instrument for samples in CHCl_3 . NMR

spectra were acquired on JEOL JMN-ECA600 and JMN-ECS400 spectrometers with tetramethylsilane as internal standard, and chemical shifts are expressed as δ values. HRMS data were obtained on a JMS-SX102A (FAB) or JMS-T100TD (DART) mass spectrometer. Microwave irradiation experiments were carried out in a dedicated Biotage Initiator 2.5 microwave apparatus. Analytical and preparative TLC was carried out on precoated silica gel 60F₂₅₄ and RP-18F₂₅₄ plates (0.25 or 0.50 mm thickness; Merck). MPLC was performed with silica gel and C₁₈ cartridges (Biotage, Uppsala Sweden). Compounds **9**–**13**^{16,17,20} and **19**²¹ were obtained previously.

1-[3-Hydroxy-7-methoxy-5-(methoxymethoxy)-2,2-dimethylchroman-8-yl]ethanone (14)—To a solution of **12** (27.4 mg, 0.09 mmol) in anhydrous CH₂Cl₂ (2.0 mL) was added 75% *m*-CPBA (25.2 mg, 0.11 mmol) at 0 °C, and the mixture was stirred for 20 min at room temperature. After consumption of **12** (TLC), montmorillonite K10 (27.3 mg) was added and stirring was continued for 30 min at room temperature. The mixture was filtered and washed with EtOAc. The organic layer was washed with saturated Na₂CO₃, H₂O, and brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:2) to afford **14** (20.0 mg, 69%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 6.33 (1H, s), 5.20 (2H, s), 3.79–3.76 (1H, m), 3.77 (3H, s), 3.49 (3H, s), 2.87 (1H, dd, *J* = 16.8, 5.4 Hz), 2.65 (1H, dd, *J* = 17.4, 6.0 Hz), 2.46 (3H, s), 1.75 (1H, d, *J* = 7.2 Hz), 1.33 (3H, s), 1.31 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 201.7, 157.2, 156.3, 151.1, 114.3, 101.6, 94.4, 90.9, 77.5, 69.1, 56.2, 56.0, 32.6, 26.1, 24.6, 21.8; HRMS (FAB) *m/z* 311.1499 [M + H]⁺ (calcd for C₁₆H₂₃O₆, 311.1495).

1-(3,5-Dihydroxy-7-methoxy-2,2-dimethylchroman-8-yl)-ethanone—To a solution of **14** (20.0 mg, 0.06 mmol) in anhydrous MeOH (1.5 mL) was added 3 N HCl (0.3 mL), and the mixture was refluxed for 1.0 h under N₂. After cooling to room temperature, the mixture was stirred for 15 min. The reaction was quenched with H₂O and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:1) to afford the deprotected compound (16.0 mg, 93%) as a colorless solid: ¹H NMR (600 MHz, CDCl₃) δ 6.00 (1H, s), 5.28 (1H, brs), 3.82–3.80 (1H, m), 3.70 (3H, s), 2.84 (1H, dd, *J* = 16.8, 4.8 Hz), 2.62 (1H, dd, *J* = 18.0, 6.6 Hz), 2.47 (3H, s), 1.91 (1H, d, *J* = 6.0 Hz), 1.34 (3H, s), 1.32 (3H, s); ¹³C NMR (150 MHz, acetone-*d*₆) δ 199.3, 156.8, 156.1, 151.6, 112.8, 100.7, 91.4, 77.5, 68.7, 55.1, 31.8, 26.0, 25.1, 19.4; HRMS (FAB) *m/z* 267.1227 [M + H]⁺ (calcd for C₁₄H₁₉O₅, 267.1232).

1-[3-Hydroxy-7-methoxy-2,2-dimethyl-5-(3-methylbut-2-enyloxy)chroman-8-yl]ethanone (15)—To a solution of 1-(3,5-dihydroxy-7-methoxy-2,2-dimethylchroman-8-yl)ethanone (10.9 mg, 0.04 mmol) and K₂CO₃ (23.0 mg, 0.17 mmol) in acetone (1.0 mL) was added prenyl bromide (0.07 mL, 0.06 mmol). The mixture was heated under reflux for 2.0 h under N₂. After cooling to room temperature, the mixture was filtered, washed with EtOAc, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:2) to afford **15** (10.4 mg, 76%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 6.07 (1H, s), 5.46–5.44 (1H, m), 4.53 (2H, d, *J* = 6.6 Hz), 3.79 (3H, s), 3.79–3.76 (1H, m), 2.85 (1H, dd, *J* = 16.8, 5.4 Hz), 2.63 (1H, dd, *J* = 17.4, 6.0 Hz), 2.47 (3H, s), 1.79

(3H, s), 1.75 (3H, s), 1.73 (1H, d, $J = 7.2$ Hz), 1.33 (3H, s), 1.30 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 201.7, 158.9, 156.5, 151.3, 138.0, 119.5, 113.3, 100.9, 89.0, 77.5, 69.1, 65.2, 56.0, 32.6, 26.1, 25.8, 24.6, 21.8, 18.3; HRMS (FAB) m/z 335.1860 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{19}\text{H}_{27}\text{O}_5$, 335.1858).

(rac)-Acronyculatin L (4)—To a solution of **15** (10.4 mg, 0.03 mmol) in anhydrous CH_2Cl_2 (0.5 mL) was added montmorillonite K10 (10.3 mg) at 0 °C. The mixture was heated in a microwave instrument at 60 °C for 4.0 h. The mixture was filtered, washed with EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with EtOAc/*n*-hexane (3:5) to afford the target **4** [4.9 mg, 66% (based on recovery of starting material)] as a yellow oil: ^1H NMR (600 MHz, CDCl_3) δ 5.74 (1H, s), 5.23–5.20 (1H, m), 3.80–3.78 (1H, m), 3.71 (3H, s), 3.35 (2H, d, $J = 7.2$ Hz), 2.87 (1H, dd, $J = 16.8, 4.8$ Hz), 2.65 (1H, dd, $J = 16.8, 5.4$ Hz), 2.50 (3H, s), 1.85 (3H, s), 1.79 (3H, s), 1.74 (1H, brs), 1.34 (3H, s), 1.32 (3H, s); ^{13}C NMR (600 MHz, CDCl_3) δ 202.2, 155.5, 154.5, 149.5, 136.3, 121.9, 118.2, 111.8, 103.6, 77.5, 69.1, 63.5, 32.7, 26.2, 25.9, 24.7, 22.8, 21.9, 18.0; HRMS (FAB) m/z 335.1850 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{19}\text{H}_{27}\text{O}_5$, 335.1858).

1-(3,5-Dihydroxy-7-methoxy-2,2-dimethylchroman-6-yl)-ethanone (16)—To a solution of **13** (48.2 mg, 0.19 mmol) in anhydrous CH_2Cl_2 (3.0 mL) was added 75% *m*-CPBA (53.2 mg, 0.23 mmol) at 0 °C, and the mixture was stirred for 20 min at room temperature. After complete consumption of **13** (TLC), montmorillonite K10 (48.3 mg) was added and the mixture was further stirred for 30 min at room temperature. The mixture was filtered and washed with EtOAc. The organic layer was washed with saturated Na_2CO_3 (aq), H_2O , and brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:2) to afford **16** (31.3 mg, 61%) as a colorless solid: ^1H NMR (600 MHz, CDCl_3) δ 14.4 (1H, s), 5.90 (1H, s), 3.85–3.82 (1H, m), 3.83 (3H, s), 2.87 (1H, dd, $J = 16.8, 4.8$ Hz), 2.65 (1H, dd, $J = 16.8, 5.4$ Hz), 2.61 (3H, s), 1.61 (1H, d, $J = 6.6$ Hz), 1.39 (3H, s), 1.33 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 203.2, 165.2, 161.5, 159.5, 105.6, 99.3, 91.1, 78.4, 69.1, 55.4, 32.9, 25.4, 24.8, 22.2; HRMS (FAB) m/z 267.1241 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{14}\text{H}_{19}\text{O}_5$, 267.1232).

1-[3-Hydroxy-7-methoxy-2,2-dimethyl-5-(3-methylbut-2-enyloxy)chroman-6-yl]ethanone (17)—To a solution of **16** (27.9 mg, 0.10 mmol) and K_2CO_3 (58 mg, 0.42 mmol) in acetone (2.0 mL) was added prenyl bromide (0.02 mL, 0.15 mmol), and the mixture was heated at reflux temperature for 20 h under N_2 . The mixture was cooled to room temperature, filtered, washed with EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with $\text{CHCl}_3/\text{MeOH}$ (20:1) to afford **17** (28.3 mg, 81%) as a colorless oil: ^1H NMR (600 MHz, CDCl_3) δ 6.21 (1H, s), 5.47–5.45 (1H, m), 4.35 (2H, d, $J = 7.2$ Hz), 3.81–3.79 (1H, m), 3.76 (3H, s), 2.92 (1H, dd, $J = 16.8, 4.8$ Hz), 2.70 (1H, dd, $J = 16.8, 5.4$ Hz), 2.50 (3H, s), 1.77 (3H, s), 1.67 (3H, s), 1.65 (1H, s), 1.36 (3H, s), 1.32 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 202.1, 156.5, 155.9, 155.2, 138.8, 119.8, 118.9, 105.4, 96.2, 91.1, 71.6, 69.3, 55.7, 32.6, 26.3, 25.8, 24.7, 22.0, 18.1; HRMS (FAB) m/z 335.1854 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{19}\text{H}_{27}\text{O}_5$, 335.1858).

(rac)-Acronyculatin K (3)—A solution of **17** (26.4 mg, 0.08 mmol) in *N,N*-diethylaniline (0.5 mL) was heated in a microwave instrument at 210 °C for 1.0 h. After cooling to room temperature, the mixture was washed with aqueous 10% HCl, H₂O, and brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:5) to afford **3** (18.5 mg, 70%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 13.6 (1H, s), 5.15–5.13 (1H, m), 3.85–3.83 (1H, m), 3.71 (3H, s), 3.26 (2H, t, *J* = 5.4 Hz), 2.91 (1H, dd, *J* = 17.4, 5.4 Hz), 2.68 (1H, dd, *J* = 17.4, 6.0 Hz), 2.69 (3H, s), 1.77 (3H, s), 1.68 (3H, s), 1.62 (1H, d, *J* = 7.2 Hz), 1.37 (3H, s), 1.32 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 203.4, 162.1, 159.1, 158.1, 131.1, 123.2, 115.0, 108.6, 103.2, 78.2, 68.9, 62.7, 30.9, 25.8, 25.7, 24.8, 22.5, 22.1, 18.0; HRMS (FAB) *m/z* 335.1852 [*M* + *H*]⁺ (calcd for C₁₉H₂₇O₅, 335.1858).

1-(3,5-Dihydroxy-8-isopentyl-7-methoxy-2,2-dimethylchroman-6-yl)ethanone (18)—To a solution of **3** (8.1 mg, 0.02 mmol) in EtOH (0.5 mL) was added Pd/C (3.3 mg). The reaction mixture was sealed and stirred at room temperature for 2.0 h under H₂. The mixture was filtered through Celite, washed with EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with CHCl₃/MeOH (30:1) to afford the target **18** (5.9 mg, 72%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 13.6 (1H, s), 3.84 (1H, q, *J* = 4.8 Hz), 3.72 (3H, s), 2.90 (1H, dd, *J* = 16.8, 5.4 Hz), 2.68 (1H, dd, *J* = 17.4, 6.0 Hz), 2.68 (3H, s), 2.55–2.51 (2H, m), 1.63–1.60 (2H, m), 1.40–1.37 (1H, m), 1.38 (3H, s), 1.33 (3H, s), 0.97 (3H, s), 0.95 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 203.4, 161.9, 159.1, 158.1, 116.3, 108.6, 103.1, 78.1, 68.9, 62.9, 39.2, 30.9, 28.4, 25.9, 24.9, 22.6, 22.6, 22.1, 21.3; HRMS (FAB) *m/z* 337.1975 [*M* + *H*]⁺ (calcd for C₁₉H₂₉O₅, 337.2015).

1-[2-Hydroxy-4,6-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl]ethanone—To a solution of **19** (167.5 mg, 0.71 mmol) in anhydrous CH₂Cl₂ (5.0 mL) was added *N,N*-diisopropylethylamine (0.35 mL, 2.01 mmol) at 0 °C, and the mixture was stirred for 20 min under Ar. MOMCl (0.13 mL, 1.71 mmol) was added, and stirring at room temperature continued for 45 min. The reaction was quenched with H₂O and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with CH₂Cl₂/*n*-hexane (1:1) to afford the target di-MOM ether (149.2 mg, 65%) as a pale yellow solid: ¹H NMR (600 MHz, CDCl₃) δ 13.8 (1H, s), 6.39 (1H, s), 5.25 (2H, s), 5.23 (2H, s), 5.21–5.18 (1H, m), 3.51 (3H, s), 3.47 (3H, s), 3.30 (2H, d, *J* = 7.2 Hz), 2.65 (3H, s), 1.78 (3H, s), 1.66 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 203.5, 163.5, 160.7, 158.8, 131.4, 122.5, 111.6, 106.9, 94.6, 93.9, 91.2, 56.7, 56.3, 33.2, 25.8, 21.6, 17.8; HRMS (FAB) *m/z* 325.1668 [*M* + *H*]⁺ (calcd for C₁₇H₂₅O₆, 325.1651).

1-[2-Methoxy-4,6-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl]ethanone—To a solution of di-MOM ether (132.6 mg, 0.41 mmol) in anhydrous DMF (5.0 mL) were added K₂CO₃ (360.0 mg, 2.61 mmol) and iodomethane (0.08 mL, 1.23 mmol). The mixture was heated at reflux temperature for 2.5 h under N₂. After cooling to room temperature, the reaction was quenched with H₂O (10.0 mL) and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:5) to afford

the methyl ether (104.6 mg, 76%) as a yellow oil: ^1H NMR (600 MHz, CDCl_3) δ 6.70 (1H, s), 5.19 (2H, s), 5.17–5.14 (1H, m), 5.14 (2H, s), 3.72 (3H, s), 3.47 (3H, s), 3.46 (3H, s), 3.29 (2H, d, $J = 7.2$ Hz), 2.52 (3H, s), 1.76 (3H, s), 1.67 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 202.2, 157.2, 156.1, 153.0, 131.3, 123.0, 120.8, 118.3, 97.9, 95.1, 94.3, 63.1, 56.4, 56.2, 32.6, 25.7, 22.7, 17.8; HRMS (FAB) m/z 339.1777 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{18}\text{H}_{27}\text{O}_6$, 339.1808).

1-[4,6-Dihydroxy-2-methoxy-3-(3-methylbut-2-enyl)-phenyl]ethanone (20)—To a solution of 1-[2-methoxy-4,6-bis-(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl]ethanone (54.7 mg, 0.16 mmol) in anhydrous MeOH (3.0 mL) was added 3 N HCl (0.6 mL), and the mixture was heated at reflux temperature for 1.5 h under N_2 . The mixture was cooled to room temperature and stirred for 15 min, quenched with H_2O (10.0 mL), and extracted with EtOAc (3×15 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:6) to afford the target **20** (31.2 mg, 77%) as a colorless solid: ^1H NMR (600 MHz, CDCl_3) δ 13.2 (1H, s), 6.53 (1H, s), 6.22 (1H, s), 5.23–5.21 (1H, m), 3.74 (3H, s), 3.35 (2H, d, $J = 7.2$ Hz), 2.69 (3H, s), 1.82 (3H, s), 1.75 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 203.7, 164.1, 162.6, 161.4, 135.0, 121.9, 113.2, 109.5, 100.5, 62.8, 31.0, 25.8, 22.7, 18.0; HRMS (FAB) m/z 251.1290 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{14}\text{H}_{19}\text{O}_4$, 251.1283).

1-(3,7-Dihydroxy-5-methoxy-2,2-dimethylchroman-6-yl)-ethanone (21)—To a solution of **20** (29.2 mg, 0.12 mmol) in anhydrous CH_2Cl_2 (3.0 mL) was added 75% *m*-CPBA (31.7 mg, 0.14 mmol) at 0 °C, and the mixture was stirred for 20 min at room temperature. After consumption of **20** (TLC), montmorillonite K10 (29.2 mg) was added and the mixture was stirred for 30 min at room temperature. The mixture was filtered and washed with EtOAc. The organic layer was washed with saturated Na_2CO_3 , H_2O , and brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:2) to afford **21** (26.4 mg, 85%) as a colorless solid: ^1H NMR (600 MHz, CDCl_3) δ 13.0 (1H, s), 6.20 (1H, s), 3.83–3.82 (1H, m), 3.78 (3H, s), 2.95 (1H, dd, $J = 16.8, 5.4$ Hz), 2.71 (1H, dd, $J = 16.8, 6.6$ Hz), 2.67 (3H, s), 1.99 (1H, d, $J = 4.2$ Hz), 1.37 (3H, s), 1.36 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 203.2, 163.7, 162.1, 160.2, 109.7, 104.9, 101.2, 78.1, 69.1, 61.5, 31.1, 26.0, 25.1, 21.8; HRMS (FAB) m/z 267.1228 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{14}\text{H}_{19}\text{O}_5$, 267.1232).

1-[3-Hydroxy-5-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyloxy)chroman-6-yl]ethanone—To a solution of **21** (28.3 mg, 0.11 mmol) and K_2CO_3 (59.7 mg, 0.43 mmol) in acetone (2.0 mL) was added prenyl bromide (0.02 mL, 0.17 mmol), and the mixture was heated at reflux temperature for 12.5 h under N_2 . The mixture was cooled to room temperature, filtered, washed with EtOAc, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:2) to afford the product (34.3 mg, 97%) as a colorless oil: ^1H NMR (600 MHz, CDCl_3) δ 6.21 (1H, s), 5.43–5.41 (1H, m), 4.45 (2H, d, $J = 7.2$ Hz), 3.82–3.79 (1H, m), 3.74 (3H, s), 2.91 (1H, dd, $J = 16.8, 4.8$ Hz), 2.68 (1H, dd, $J = 13.8, 6.0$ Hz), 2.50 (3H, s), 1.77 (3H, s), 1.69 (3H, s), 1.67 (1H, d, $J = 6.6$ Hz), 1.36 (3H, s), 1.32 (3H, s); ^{13}C NMR (150 MHz, CDCl_3) δ 202.1, 156.8, 156.1, 155.2, 137.9,

119.3, 118.8, 105.0, 101.3, 97.2, 69.1, 65.5, 62.1, 32.6, 26.0, 25.7, 24.8, 21.9, 18.2; HRMS (FAB) m/z 335.1870 $[M + H]^+$ (calcd for $C_{19}H_{27}O_5$, 335.1858).

(rac)-Acronyculatin I (1)—To a solution of 1-[3-hydroxy-5-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyloxy)chroman-6-yl]-ethanone (34.3 mg, 0.10 mmol) in anhydrous CH_2Cl_2 (0.5 mL) was added montmorillonite K10 (34.4 mg) at 0 °C, and the mixture was stirred for 3.0 h at room temperature. The mixture was filtered, washed with EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with EtOAc/*n*-hexane (1:1) to afford **1** (18.8 mg, 55%) as a colorless solid. The physical data (1H NMR, ^{13}C NMR, HRMS) were essentially identical to the reported data for the natural product.⁹

(rac)-Acronyculatin J (2)—To a solution of **1** (7.6 mg, 0.02 mmol) in EtOH (0.5 mL) was added Pd/C (3.6 mg). The reaction mixture was sealed and stirred at room temperature for 2.0 h under H_2 . The mixture was filtered through Celite, washed with EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with $CHCl_3$ /MeOH (30:1) to afford **2** (5.7 mg, 75%) as a colorless oil. The physical data (1H NMR, ^{13}C NMR, HRMS) were essentially identical to the reported data for the natural product.⁹

1-[2-Allyloxy-4,6-bis(methoxymethoxy)phenyl]ethanone—To a mixture of **9** (71.9 mg, 0.28 mmol) and K_2CO_3 (152.6 mg, 1.10 mmol) in acetone (3.0 mL) was added dropwise a solution of allyl bromide (0.07 mL, 0.83 mmol) in acetone (0.9 mL). The reaction mixture was stirred under reflux for 28 h. The mixture was cooled to room temperature, filtered, and evaporated in vacuo. The residue was extracted with CH_2Cl_2 (3×15 mL). The combined organic layers were washed with saturated $NaHCO_3$ and brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified with column chromatography on silica gel to obtain the product (72.3 mg, 0.24 mmol, 86%) as a pale yellow oil: 1H NMR (400 MHz, $CDCl_3$) δ 6.46 (1H, s, $J = 2.0$ Hz), 6.31 (1H, d, $J = 2.0$ Hz), 6.04–5.94 (1H, m), 5.40–5.35 and 5.28–5.25 (2H, each m), 5.14 (4H, d, $J = 4.4$ Hz), 4.53–4.51 (2H, m), 3.47 (6H, d, $J = 5.6$ Hz), 2.49 (3H, s); ^{13}C NMR (150 MHz, $CDCl_3$) δ 201.6, 159.6, 156.8, 155.3, 132.6, 117.7, 116.2, 96.2, 95.0, 94.8, 94.4, 69.4, 56.3, 56.2, 32.5; HRMS (FAB) m/z 297.1338 $[M + H]^+$ (calcd for $C_{15}H_{21}O_6$, 297.1355).

1-[2-Hydroxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)-phenyl]ethanone (22)—A solution of 1-[2-allyloxy-4,6-bis-(methoxymethoxy)phenyl]ethanone (104.6 mg, 0.35 mmol) in *N,N*-diethylaniline (0.5 mL) was irradiated in a microwave oven for 1 h at 210 °C. The mixture was cooled to room temperature and the reaction quenched with ice-cooled 15% aqueous HCl. The residue was extracted three times with CH_2Cl_2 (3×15 mL). The combined organic layers were washed with H_2O , dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified with column chromatography on silica gel to obtain **22** (83.5 mg, 0.28 mmol, 83% based on recovery of starting material) as a pale yellow oil: 1H NMR (400 MHz, $CDCl_3$) δ 13.9 (1H, s), 6.40 (1H, s), 5.98–5.90 (1H, m), 5.26 (2H, s), 5.23 (2H, s), 5.03–4.93 (2H, m), 3.52 (3H, s), 3.47 (3H, s), 3.38–3.36 (2H, m), 2.66 (3H, s).

1-[2-Methoxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)-phenyl]ethanone—Iodomethane (0.023 mL, 0.37 mmol) was added to a solution of **22** (43.1 mg, 0.15 mmol) and K_2CO_3 (104.3 mg, 0.75 mmol) in DMF (2.0 mL), and the mixture was heated under

reflux for 3 h. The mixture was cooled to room temperature and quenched with H₂O (20 mL). The residue was extracted with EtOAc (3 × 15 mL), and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified using column chromatography on silica gel to obtain the product (39.6 mg, 0.13 mmol, 87% based on recovery of starting material) as a pale yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 6.71 (1H, s), 6.00–5.91 (1H, m), 5.17 (2H, s), 5.14 (2H, s), 5.00–4.95 (2H, m), 3.12 (3H, s), 3.46 (3H, s), 3.46 (3H, s), 3.36–3.35 (2H, m), 2.51 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 202.2, 157.3, 156.3, 153.3, 136.8, 120.8, 116.4, 114.6, 97.8, 95.0, 94.4, 63.4, 56.4, 56.3, 32.6, 27.7; HRMS (FAB) *m/z* 311.1491 [M + H]⁺ (calcd for C₁₆H₂₃O₆, 311.1495).

1-[2-Hydroxy-3-(2-propenyl)-4,6-dihydroxyphenyl]-ethanone (23)—A solution of 1-[2-methoxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)phenyl]ethanone (33.7 mg, 0.11 mmol) in MeOH (1.0 mL) was treated with HCl (0.09 mL, 0.18 mmol), and the mixture was heated under reflux for 7 h. The mixture was cooled to room temperature, quenched with H₂O (10 mL), and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified with column chromatography on silica gel to obtain **23** (19.3 mg, 0.09 mmol, 90%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 13.2 (1H, s), 6.25 (1H, s), 6.09–6.02 (1H, m), 5.61 (1H, s), 5.21–5.18 and 5.15–5.14 (2H, each m), 3.75 (3H, s), 3.44–3.41 (2H, m), 2.70 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ 203.6, 164.4, 161.9, 161.9, 136.2, 116.4, 111.0, 109.8, 100.6, 63.1, 31.0, 27.8.

(rac)-Acronyculatin N (5)—A solution of **23** (4.3 mg, 0.02 mmol) in 1,4-dioxane (0.26 mL) was treated with 2% OsO₄/*tert*-BuOH (50 μL, 0.004 mmol), and the mixture was stirred in the dark at room temperature. After 30 min, 1.3% NaIO₄/H₂O (0.8 mL, 0.05 mmol) was added dropwise. The reaction was quenched with H₂O (5 mL) and extracted with EtOAc (3 × 7 mL). The combined organic layers were washed with 20% aqueous Na₂S₂O₃, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified with column chromatography on silica gel to obtain **5** (3.1 mg, 0.013 mmol, 65%) as a colorless solid. The physical data (¹H NMR, ¹³C NMR, HRMS) were essentially identical to the reported data for the natural product.⁹

1-[2,4-Bis(*tert*-butyldimethylsilyloxy)-6-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone—To a solution of **24** (95.9 mg, 0.32 mmol) in anhydrous *N,N*-dimethylformamide (1.0 mL) were added 4-dimethylaminopyridine (3.8 mg, 0.03 mmol) and imidazole (68 mg, 1.00 mmol) at room temperature. The mixture was cooled to 0 °C, and then TBSCl (101.0 mg, 0.67 mmol) was added. The resulting mixture was allowed to warm to room temperature and was stirred for 45 min. The reaction mixture was adjusted to pH 1 by addition of 1 N HCl and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with CH₂Cl₂/*n*-hexane (1:6) to afford the title compound (51.7 mg, 31%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 12.0 (1H, s), 5.17–5.14 (2H, m), 3.26 (2H, d, *J* = 6.6 Hz), 3.20 (2H, d, *J* = 5.4 Hz), 2.58 (3H, s), 1.72 (3H, s), 1.68 (3H, s), 1.66 (3H, s), 1.64 (3H, s), 1.05 (9H, s), 1.01 (9H, s), 0.19 (6H, s), 0.04 (6H, s); ¹³C NMR

(150 MHz, CDCl₃) δ 204.5, 158.9, 158.0, 153.3, 131.5, 131.1, 124.3, 124.3, 123.2, 117.3, 114.7, 112.6, 31.4, 26.1, 25.9, 25.7, 25.4, 24.4, 23.5, 18.8, 18.2, 18.1, 18.0, -3.03, -4.19; HRMS (FAB) m/z 533.3443 [M + H]⁺ (calcd for C₃₀H₅₃O₄Si₂, 533.3482).

1-[2,4-Bis(*tert*-butyldimethylsilyloxy)-6-methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone—A 60% NaH (10.0 mg) solution was washed with *n*-hexane (0.5 mL) and dissolved in anhydrous THF (0.5 mL). The mixture was cooled to 0 °C, and 1-[2,4-bis(*tert*-butyldimethylsilyloxy)-6-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone (22.6 mg, 0.04 mmol) in anhydrous THF (0.5 mL) and dimethyl sulfate (0.02 mL, 0.19 mmol) were added under N₂. The mixture was allowed to warm to room temperature and stirred for 3.0 h. The reaction mixture was then adjusted to pH 8 by addition of saturated aqueous NH₄Cl and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:20) to afford the product (21.1 mg, 91%) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 5.17–5.13 (2H, m), 3.65 (3H, s), 3.24 (4H, m), 2.50 (3H, s), 1.69 (3H, s), 1.66 (3H, s), 1.65 (3H, s), 1.63 (3H, s), 1.00 (9H, s), 0.99 (9H, s), 0.21 (6H, s), 0.07 (6H, s); ¹³C NMR (150 MHz, CDCl₃) δ 202.7, 154.4, 154.0, 149.1, 131.1, 130.9, 123.9, 123.6, 121.7, 121.2, 62.7, 32.9, 26.1, 26.0, 25.6, 25.4, 24.8, 24.0, 18.7, 18.4, 18.1, 18.0, -3.20, -3.72; HRMS (FAB) m/z 547.3659 [M + H]⁺ (calcd for C₃₀H₅₅O₄Si₂, 547.3639).

1-[4-(*tert*-Butyldimethylsilyloxy)-2-hydroxy-6-methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone (25)—To a solution of 1-[2,4-bis(*tert*-butyldimethylsilyloxy)-6-methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone (14.8 mg, 0.03 mmol) in anhydrous THF (0.2 mL) were added TFA (0.1 mL) and H₂O (0.1 mL). The mixture was stirred at room temperature for 1.0 h. The reaction mixture was adjusted to pH 7 by addition of saturated aqueous NaHCO₃ and extracted with CH₂Cl₂ (3 × 5 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified using preparative TLC with EtOAc/*n*-hexane (1:12) to afford **25** (12.7 mg, 92%) as a yellow oil: ¹H NMR (600 MHz, CDCl₃) δ 13.2 (1H, s), 5.17–5.14 (1H, m), 5.13–5.11 (1H, m), 3.66 (3H, s), 3.26 (4H, t, *J* = 6.6 Hz), 2.68 (3H, s), 1.72 (3H, s), 1.71 (3H, s), 1.67 (3H, s), 1.66 (3H, s), 1.00 (9H, s), 0.21 (6H, s); ¹³C NMR (150 MHz, CDCl₃) δ 203.9, 161.7, 159.3, 158.8, 131.8, 131.1, 123.7, 122.8, 118.4, 117.3, 110.4, 62.5, 31.0, 26.1, 25.7, 25.5, 23.8, 23.5, 18.9, 18.0, -3.05; HRMS (FAB) m/z 433.2733 [M + H]⁺ (calcd for C₂₅H₄₁O₄Si, 433.2774).

2-Acetyl-5-(*tert*-butyldimethylsilyloxy)-3-methoxy-4,6-bis(3-methylbut-2-enyl)phenyl Acetate (26)—To a solution of **25** (58.9 mg, 0.14 mmol) in pyridine (1.0 mL) were added DMAP (2.3 mg, 0.02 mmol) and Ac₂O (0.06 mL, 0.68 mmol), and the mixture was stirred at room temperature for 1.0 h. The reaction mixture was adjusted to pH 4 by addition of 1 N HCl and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:10) to afford **26** (56.4 mg, 87%) as a colorless oil: ¹H NMR (600 MHz, CDCl₃) δ 5.14–5.12 (1H, m), 5.02–4.99 (1H, m), 3.65 (3H, s), 3.30 (2H, d, *J* = 6.6 Hz), 3.19 (2H, d, *J* = 6.0 Hz), 2.52 (3H, s), 2.17 (3H, s),

1.71 (3H, s), 1.67 (3H, s), 1.67 (3H, s), 1.66 (3H, s), 1.00 (9H, s), 0.19 (6H, s); ^{13}C NMR (100 MHz, CDCl_3) δ 201.5, 169.3, 155.6, 154.1, 144.9, 131.6, 131.5, 124.7, 123.0, 122.5, 122.4, 62.8, 31.3, 26.0, 25.6, 25.5, 24.5, 24.1, 20.8, 18.8, 18.0, 17.9, -3.11; HRMS (FAB) m/z 475.2862 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{27}\text{H}_{43}\text{O}_5\text{Si}$, 475.2880).

2-Acetyl-5-[(*tert*-butyldimethylsilyl)oxy]-6-[(3,3-dimethyloxiran-2-yl)methyl]-3-methoxy-4-(3-methylbut-2-en-1-yl)phenyl Acetate (28a) and 2-Acetyl-5-[(*tert*-butyldimethylsilyl)oxy]-4-[(3,3-dimethyloxiran-2-yl)methyl]-3-methoxy-6-(3-methylbut-2-en-1-yl)phenyl Acetate (28b)—To a solution of **26** (12.9 mg, 0.03 mmol) in anhydrous CH_2Cl_2 (0.5 mL) was added 75% *m*-CPBA (6.2 mg, 0.03 mmol) at -70°C , and the mixture was stirred for 30 min. The reaction mixture was adjusted to pH 7 by addition of saturated aqueous Na_2CO_3 and extracted with CH_2Cl_2 (3×5 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc/*n*-hexane (1:5) to afford a mixture of the target compounds **28a** and **28b** [6.1 mg, 77% (based on recovery of starting material)] as a yellow oil.

5-Acetyl-2-(2-hydroxypropan-2-yl)-6-methoxy-7-(3-methyl-but-2-en-1-yl)-2,3-dihydrobenzofuran-4-yl Acetate (29) and 5-Acetyl-2-(2-hydroxypropan-2-yl)-4-methoxy-7-(3-methylbut-2-en-1-yl)-2,3-dihydrobenzofuran-6-yl Acetate (30)—To a mixture of **28a** and **28b** (6.1 mg, 0.01 mmol) in anhydrous THF (0.5 mL) were added HOAc (2.0 μL , 0.03 mmol) and TBAF (15.0 μL , 0.015 mmol), and the mixture was stirred at 0°C for 10 min under Ar. To the mixture was added *p*-TsOH (2.4 mg, 0.01 mmol), and the mixture was stirred for 1.0 h. The mixture was adjusted to pH 7 by addition of saturated aqueous NaHCO_3 and extracted with EtOAc (3×5 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified using preparative TLC with EtOAc/*n*-hexane (1:2) to afford **29** (1.3 mg, 27%) and **30** (2.9 mg, 64%) as yellow oils.

5-Acetyl-2-(2-hydroxypropan-2-yl)-6-methoxy-7-(3-methyl-but-2-enyl)-2,3-dihydrobenzofuran-4-yl Acetate (29)— ^1H NMR (600 MHz, CDCl_3) δ 5.20–5.17 (1H, m), 4.68 (1H, t, $J = 8.4$ Hz), 3.70 (3H, s), 3.28 (2H, d, $J = 7.8$ Hz), 3.02–2.99 (2H, m), 2.51 (3H, s), 2.25 (3H, s), 1.76 (3H, s), 1.70 (3H, s), 1.30 (3H, s), 1.19 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ 168.6, 166.1, 160.8, 157.5, 153.2, 132.3, 121.7, 116.3, 115.3, 90.5, 77.2, 71.8, 63.4, 31.5, 28.4, 25.7, 25.6, 24.0, 23.0, 20.7, 17.8; HRMS (FAB) m/z 377.1975 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{21}\text{H}_{29}\text{O}_6$, 377.1964).

5-Acetyl-2-(2-hydroxypropan-2-yl)-4-methoxy-7-(3-methyl-but-2-enyl)-2,3-dihydrobenzofuran-6-yl Acetate (30)— ^1H NMR (600 MHz, CDCl_3) δ 5.11–5.08 (1H, m), 4.66 (1H, t, $J = 9.6$ Hz), 3.86 (3H, s), 3.29–3.27 (2H, m), 3.16 (1H, dd, $J = 15.0, 7.8$ Hz), 3.10 (1H, dd, $J = 14.4, 6.6$ Hz), 2.46 (3H, s), 2.24 (3H, s), 1.72 (3H, s), 1.67 (3H, s), 1.35 (3H, s), 1.23 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ 200.3, 169.5, 161.1, 152.8, 146.5, 132.2, 121.1, 114.0, 112.1, 90.1, 77.2, 71.6, 59.9, 31.8, 29.4, 26.0, 25.7, 24.3, 23.4, 20.7, 17.8; HRMS (FAB) m/z 377.1958 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{21}\text{H}_{29}\text{O}_6$, 377.1964).

(rac)-Acronyculatin O (6)—To a solution of **29** (2.0 mg, 0.005 mmol) in anhydrous MeOH (0.1 mL) was added Ba(OH)₂ (0.1 mL, 0.01 mmol, 0.1 M in MeOH), and the mixture was stirred for 30 min at room temperature. The mixture was directly purified using preparative TLC with CHCl₃/MeOH (20:1) to afford **6** (1.1 mg, 56%) as a colorless solid. The physical data (¹H NMR, ¹³C NMR, HRMS) were essentially identical to the reported data for the natural product.⁹

(rac)-Acronyculatin B (7)—To a solution of **30** (5.3 mg, 0.02 mmol) in anhydrous MeOH (0.2 mL) was added Ba(OH)₂ (0.2 mL, 0.02 mmol, 0.1 M in MeOH), and stirring continued for 30 min at room temperature. The mixture was directly purified using preparative TLC with CHCl₃/MeOH (20:1) to afford **7** (2.5 mg, 53%) as a colorless solid. The physical data (¹H NMR, ¹³C NMR, HRMS) were essentially identical to the reported data for the natural product.⁹

In Vitro EBV-EA Activation Experiments

The anti-tumor-promoting activities of compounds were assessed using the EBV-EA activation assay in the presence of 32 pmol/mL TPA as described before.^{26,27} The average EBV-EA induction of the test compound was determined as a ratio relative to the control. The viability of treated Raji cells was evaluated by trypan blue staining.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

We appreciate critical comments, suggestions, and editing of the manuscript by Dr. S. L. Morris-Natschke (UNC-CH). This work was supported by JSPS KAKENHI Grant Number JP25293024 awarded to K.N.G. This study was also supported in part by a grant from the National Cancer Institute/NIH (CA177584), awarded to K.H.L.

References


1. Adersen A, Smitt UW, Simonsen HT, Christensen SB, Jaroszewski JW. *Biochem Syst Ecol.* 2007; 35:447–453.
2. Edayadulla N, Ramesh P. *Nat Prod Commun.* 2012; 7:1325–1326. [PubMed: 23157000]
3. Pisco L, Kordian M, Peseke K, Feist H, Michalik D, Estrada E, Carvalho J, Hamilton G, Rando D, Quincoces J. *Eur J Med Chem.* 2006; 41:401–407. [PubMed: 16443308]
4. Banerji J, Rej RN, Chatterjee A. *Indian J Chem.* 1973; 11:693–694.
5. Funayama S, Cordell GA. *J Nat Prod.* 1984; 47:285–291. [PubMed: 6736969]
6. Wu TS, Wang ML, Jong TT. *J Nat Prod.* 1989; 52:1284–1289. [PubMed: 2614422]
7. Oyama M, Bastow KF, Tachibana Y, Shirataki Y, Yamaguchi S, Cragg GM, Wu TS, Lee KH. *Chin Pharm J.* 2003; 55:239–245.
8. Kouloura E, Halabalaki M, Lallemand MC, Nam S, Jove R, Litaudon M, Awang K, Hadi HA, Skaltsounis AL. *J Nat Prod.* 2012; 75:1270–1276. [PubMed: 22708987]
9. Miyake K, Suzuki A, Morita C, Goto M, Newman DJ, O'Keefe B, Morris-Natschke SL, Lee KH, Nakagawa-Goto K. *J Nat Prod.* 2016; doi: 10.1021/acs.jnatprod.6b00645
10. Su CR, Kuo PC, Wang ML, Liou MJ, Damu AG, Wu TS. *J Nat Prod.* 2003; 66:990–993. [PubMed: 12880321]

11. Nakagawa-Goto K, Bastow KF, Wu JH, Tokuda H, Lee KH. *Bioorg Med Chem Lett*. 2005; 15:3016–3019. [PubMed: 15913998]
12. Nakamura ES, Kurosaki F, Arisawa M, Mukainaka T, Okuda M, Tokuda H, Nishino H, Pastore F. *Cancer Lett*. 2002; 177:119–124. [PubMed: 11825658]
13. Hung HY, Nakagawa-Goto K, Tokuda H, Iida A, Suzuki N, Morris-Natschke SL, Lee KH. *Pharm Biol*. 2012; 50:18–24. [PubMed: 22196579]
14. Tatsuzaki J, Nakagawa-Goto K, Tokuda H, Lee KH. *J Asian Nat Prod Res*. 2010; 12:227–232. [PubMed: 20390770]
15. Nakagawa-Goto K, Yamada K, Taniguchi M, Tokuda H, Lee KH. *Bioorg Med Chem Lett*. 2009; 19:3378–3381. [PubMed: 19481937]
16. Suzuki M, Nakagawa-Goto K, Nakamura S, Tokuda H, Morris-Natschke SL, Kozuka M, Nishino H, Lee KH. *Pharm Biol*. 2006; 44:178–182.
17. Khupse RS, Erhardt PW. *J Nat Prod*. 2007; 70:1507–1509. [PubMed: 17844997]
18. Tan WF, Li WD, Li YL. *Synth Commun*. 2002; 32:1077–1083.
19. Sugamoto K, Matsusita Y, Matsui K, Kurogi C, Matsui T. *Tetrahedron*. 2011; 67:5346–5359.
20. Dintzner MR, Morse KM, McClelland KN, Coligado DM. *Tetrahedron Lett*. 2004; 45:79–81.
21. Vogel S, Heilmann J. *J Nat Prod*. 2008; 71:1237–1241. [PubMed: 18611049]
22. Baptista FR, Pinto DCGA, Silva AMS. *Synlett*. 2014; 25:1116–1120.
23. Minassi A, Giana A, Ech-Chahad A, Appendino G. *Org Lett*. 2008; 10:2267–2270. [PubMed: 18454537]
24. Hung HY, Nakagawa-Goto K, Tokuda H, Iida A, Suzuki N, Qian K, Lee KH. *Bioorg Med Chem Lett*. 2014; 24:1005–1008. [PubMed: 24411124]
25. Wang X, Nakagawa-Goto K, Kozuka M, Tokuda H, Nishino H, Lee KH. *Pharm Biol*. 2006; 44:116–120.
26. Henle G, Henle W. *J Bacteriol*. 1966; 91:1248–1256. [PubMed: 4160230]
27. Suzuki A, Miyake K, Saito Y, Rasyid FA, Tokuda H, Takeuchi M, Suzuki N, Ichiishi E, Fujie T, Goto M, Sasaki Y, Nakagawa-Goto K. *Planta Med*. 2016; doi: 10.1055/s-0042-110858



Scheme 1. Total Synthesis of Racemic Acetophenone Monomers 1–5^a

^aConditions: (a) MOMCl, DIPEA, CH₂Cl₂, rt; (b) prenyl-Br, K₂CO₃, acetone, reflux; (c) PhNEt₂, microwave, 210 °C; (d) MeI, K₂CO₃, DMF, reflux; (e) 3 N HCl/MeOH (1:10), reflux; (f) 3 N HCl/MeOH (1:5), reflux; (g) mCPBA, CH₂Cl₂, rt, 20 min, then montmorillonite K10 (M-K10), 30 min; (h) M-K10, CH₂Cl₂, microwave, 60 °C; (i) M-K10, CH₂Cl₂, 0 °C to rt; (j) Pd/C, H₂, EtOH, rt; (k) prenyl-Br, DBU, THF, rt; (l) allyl-Br, K₂CO₃, acetone, reflux; (m) 2% OsO₄, NaIO₄, 1,4-dioxane, rt. *rsm: recovery of starting material.



Scheme 2. Preparation of Racemic Acetophenone Monomers 6 and 7^a

^aConditions: (a) prenyl-Br, 10% KOH_{aq}, CH₂Cl₂, rt, 1.5 h, 46%; (b) TBSCl, imidazole, DMAP, DMF, 85 °C, 45 min, 31%; (c) Me₂SO₄, NaH, THF, rt, 3.0 h, 91%; (d) TFA/H₂O, THF, rt, 1.0 h, 92%; (e) Ac₂O, DMAP, Py, rt, 1.0 h, 87%; (f) *m*CPBA, CH₂Cl₂, -70 °C, 30 min; (g) TBAF, HOAc, THF, 0 °C to rt, 1 h, 27% for 29, 64% for 30; (h) 0.1 M Ba(OH)₂, MeOH, 30 min, rt, 56% for **6**, 53% for **7**.

Table 3
Relative Ratio^a of EBV-EA Activation with Respect to Positive Control (100%)

	percentage EBV-EA positive cells				
	concentration (mol ratio/TPA) ^b				
	1000	500	100	10	IC ₅₀ (μM) ^c
1	0.0 ± 0.3 (60) ^d	26.5 ± 1.4	65.5 ± 2.5	92.4 ± 0.5	7.3
2	4.9 ± 0.2 (60)	31.5 ± 1.4	76.0 ± 2.6	97.7 ± 0.6	9.3
3	3.0 ± 0.3 (60)	29.1 ± 1.4	72.5 ± 2.4	96.9 ± 0.5	8.9
4	1.5 ± 0.2 (60)	27.1 ± 1.1	68.2 ± 2.5	96.6 ± 0.5	8.4
5	10.8 ± 0.5 (60)	53.3 ± 1.6	77.9 ± 2.2	100 ± 0.3	15.7
6	0.0 ± 0.3 (60)	32.0 ± 1.5	75.5 ± 2.3	94.9 ± 0.4	8.0
7	0.0 ± 0.3 (60)	30.6 ± 1.5	74.3 ± 2.5	93.3 ± 0.4	7.7
18	0.0 ± 0.4 (60)	36.6 ± 1.5	78.8 ± 2.3	97.8 ± 0.3	8.1
29	7.0 ± 0.6 (60)	43.8 ± 1.2	71.0 ± 2.3	100 ± 0.3	15.0
30	5.3 ± 0.5 (60)	33.9 ± 1.5	78.6 ± 2.4	97.8 ± 0.5	9.9
curcumin	0.0 ± 0.4 (60)	21.1 ± 1.1	80.1 ± 2.4	100 ± 0.1	12.1

^aValues represent percentages relative to the positive control value (100%).

^bTPA concentration is 32 nM.

^cThe concentration of compound required to inhibit 50% of the positive control activated with 32 nM TPA.

^dValues in parentheses are viability percentages of Raji cells.